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We have reviewed scientific literature about the association of systemic sclerosis (SSc) 
and thyroid disorders. A high incidence, and prevalence, of new cases of autoimmune 
thyroiditis (AT) and/or hypothyroidism have been shown in sclerodermic patients (overall 
in the female gender). An association among a Th1 immune-predominance, low vitamin 
D levels, and AT have been also shown in SSc patients. Cases of Graves’ disease (GD) 
have been described in SSc patients, too, according with the higher prevalence of 
thyroid autoimmunity. It has been also shown a higher prevalence of papillary thyroid 
cancer (PTC), in association with AT, in SSc patients. However, in order to confirm results 
about GD and thyroid cancer, studies in larger number of patients with SSc are needed. 
During the follow-up of SSc patients it would be appropriate to monitor carefully their 
thyroid status. The abovementioned data strongly suggest a periodic thyroid function 
follow-up in female SSc patients [showing a borderline high (although in the normal range) 
thyroid-stimulating hormone level, antithyroid peroxidase antibody positivity, and a small 
thyroid with a hypoechoic pattern], and, when necessary, appropriate treatments. In 
conclusion, most of the studies show an association among SSc, AT, and hypothyroid-
ism, such as an increased prevalence of TC overall in SSc patients with AT. Only few 
cases of GD have been also described in SSc.
Keywords: systemic sclerosis, autoimmune thyroiditis, hypothyroidism, Graves’ disease, thyroid cancer, 
antithyroperoxidase antibodies, antithyroglobulin antibodies, CXCL10
INTRODUCTION
Systemic sclerosis (SSc) is a connective tissue disease characterized by degenerative microvascular 
phenomena and immune system activation, that lead to fibrosis of the skin and internal organs 
(1, 2). SSc is clinically a multifaceted disorder derived from different contributions of the above-
mentioned pathogenetic mechanisms, through a multistep process that causes various clinical 
phenotypes (3). SSc is a heterogeneous autoimmune disease which has defined by three hallmarks: 
small vessel vasculopathy, production of autoantibodies, and fibroblast dysfunction. The exact etiol-
ogy of the disease remains unknown, due to the complex nature of the cellular signaling pathways 
involved. However, there is strong and consistent evidence that the innate system, in particular 
Abbreviations: AbTg, antithyroglobulin antibodies; AbTPO, antithyroid peroxidase antibodies; AITD, autoimmune thy-
roid disorders; AT, autoimmune thyroiditis; ATA, antithyroid antibodies; dcSSC, diffuse cutaneous scleroderma; FT3, free 
triiodothyronine; FT4, free thyroxine; GD, Graves’ disease; HC, healthy controls; HT, Hashimoto’s thyroiditis; lSSc, limited 
cutaneous scleroderma; MCTD, mixed connective tissue disease; OA, osteoarthritis; OR, odds ratios; PM/DM, polymyositis/
dermatomyositis; PTC, papillary thyroid cancer; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s 
syndrome; SSc, systemic sclerosis; TC, thyroid cancer; TSH, thyroid-stimulating hormone.
TABLE 1 | Prevalence of thyroid autoimmunity in SSc patients versus controls, in the published studies that included an internal control group.
Reference SSc patients (n) AITD% in SSc patients Controls (n) AITD% in controls P
Gordon et al. (11) 56 14 56 2 <0.05
Shahin et al. (17) 24 Serum levels of FT4 in patients were significantly 
lower than in controls (7.46 ± 2.7 for patients 
versus 10.5 ± 1.8 for controls with P < 0.001). 
Of the 24 patients, 8 (33.3%) showed 
hypothyroidism, evidenced by decreased FT4 
and increased TSH beyond normal ranges, 5/14 
(32.7%) with dSSc versus 3/10 (30%) with lSSc 
(P = ns)
15
Innocencio et al. (18) 25 52 113 3.5
Antonelli et al. (20) F 184; M 18 F 107/77 (58%); M 7/11 (39%) F 368; M 36 F 100/268 (27%); M 2/34 
(6%)
F 0.0001; M 0.0019
Marasini et al. (21) 79 AbTg in 14% of patients; AbTPO in 23% of 
patients
81 women with OA 
serving as controls
AbTg in 13% of patients; 
AbTPO in 11% of patients
ns (for AbTg); 0.057 
(for AbTPO)
Danielides et al. (23) 138 AbTPO and/or AbTg positive in 29% of patients 100 AbTPO and/or AbTg 
positive in 29% of controls
ns
Antonelli et al. (25) 179 24% (initial thyroid status); 34% (last thyroid 
status)
179 12% (initial thyroid status); 
16% (last thyroid status)
0.002 (initial thyroid 
status); <0.001 (last 
thyroid status)
AbTg, antithyroglobulin antibodies; AbTPO, antithyroperoxidase antibodies; F, female; FT4, free thyroxine; M, male; ns, not significant; OA, osteoarthritis; TSH, thyroid-stimulating 
hormone.
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toll-like receptor signaling, is contributing to the progression 
and perhaps onset of SSc (4).
Two overlapping SSc forms exist: (a) a limited cutaneous scle-
roderma (lSSc), confined to the skin of face, hands and feet and 
(b) a diffuse cutaneous scleroderma (dcSSc), extended over other 
areas of the skin, that can involve visceral organs, as kidneys, 
lungs, heart, and gastrointestinal tract. Patients affected by the 
limited form show a good prognosis, with a 10-year survival in 
about 75% of patients; however, about 10% of them develop pul-
monary arterial hypertension after 15 years. Patients with dcSSc 
have a 10-year survival of 55%; death is commonly associated 
with pulmonary, heart, and kidney involvement.
The diagnosis is established on the basis of clinical suspicion, 
the presence of autoantibodies (in particular anticentromere 
and anti-scl70/antitopoisomerase antibodies) and quite rarely 
on biopsy. Regarding the antibodies, 90% of SSc patients have 
a detectable antinuclear antibody; anticentromere antibody is 
more frequent in lSSc (80–90%) compared to dcSSc (10%), and 
anti-scl70 is more common in dcSSc (30–40%) (5).
The American College of Rheumatology set the diagnostic 
criteria for scleroderma in 1980 (6).
Systemic sclerosis is associated with significant morbidity 
(including skin thickening, finger ulcers, joint contractures, 
pulmonary fibrosis and hypertension, chronic diarrhea, and 
renal failure) (7).
Systemic sclerosis patients have high rates of symptoms of 
depression, and SSc is associated with substantially reduced 
health-related quality of life (8).
Many studies show a high prevalence of autoimmune thyroid 
disorders (AITDs) in SSc patients; however, contradictory results 
have been reported too. Here, we review the scientific literature 
about the possible association of SSc with autoimmune thyroiditis 
(AT), Graves’ disease (GD), and also thyroid cancer (TC).
SSc AND AT
After the initial case reports (9, 10), the association of SSc and 
AITD has been evaluated by many studies (Table 1).
A first systematic study (11) reviewed patients with fatal SSc 
about pathologic and serologic evidence of thyroid disorders. 
Histologic evidence of severe fibrosis of the thyroid was reported 
in 14% of 56 SSc cases (versus 2% of age- and gender-matched 
control autopsy series). Among 27 SSc patients in whom thyroid-
stimulating hormone (TSH) and free thyroid hormones were 
measured, 7 (26%) were hypothyroid, and 9 had euthyroid sick 
syndrome. Hypothyroid patients had thyroid glands with fibrosis, but 
a few lymphocytic infiltration. However, 6/7 of hypothyroid patients 
had elevated levels of circulating antithyroglobulin antibodies 
(AbTg). These findings suggested a thyroid autoimmune process 
leading to gland fibrosis and hypothyroidism in severe SSc patients.
A second study (12) found decreased free thyroxine (FT4), 
decreased free triiodothyronine (FT3), and increased TSH in 42 
SSc patients, versus age and gender controls. However, changes in 
FT4, FT3, and TSH were small with mean values within normal 
ranges, suggesting a subclinical thyroid dysfunction.
In a further study, 77 SSc patients were evaluated by meas-
urements of basal FT4, FT3, TSH, and the TSH response to 
thyrotropin-releasing hormone (13). Eight patients (10%) were 
hypothyroid. Antithyroid antibodies (ATA) were present in four 
of eight (50%) of the hypothyroid patients.
Among 39 SSc patients (14), 2 patients had clinical hypothy-
roidism, while 7 had subclinical hypothyroidism. On the whole 
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9/39 (23%) of SSc patients were hypothyroid, and 4/9 (44%) had 
positive ATA. Circulating AbTg and/or antimicrosomal antibod-
ies were positive in 18% of the 39 patients.
A high prevalence of thyroid autoimmunity (15) was also 
observed in 43 Hungarian SSc patients. ATA were detected in 
14 cases (33%) [4 cases with AbTg, 11 with antithyroperoxidase 
antibodies (AbTPO), and 5 with antimicrosomal antibodies].
Antithyroglobulin antibodies and AbTPO antibodies, FT3, FT4 
and TSH, and HLA-DR typing were carried out in 85 SSc Italian 
patients (16). AbTg and AbTPO antibodies were detected in 12% 
(10/85) and 19% (16/85) of patients. Two patients with ATA had 
clinical hypothyroidism and shared the HLA-DR3 allele. A higher 
frequency of the HLA-DR15 was shown in SSc subjects in the 
presence of AbTPO antibodies than in patients without AbTPO.
Twenty-three female patients with SSc (mean age 37.7 ± 12.7) 
were evaluated for thyroid dysfunctions versus 15 normal females 
as controls (17). Mean serum levels of FT4 in SSc patients were 
significantly lower than in controls (7.46 ± 2.7 versus 10.47 ± 2.5). 
Of the 24 patients, 8 (33.3%) showed hypothyroidism (17).
Another Latin American study confirmed a high prevalence of 
thyroid autoantibodies in Brasilian patients with SSc (18).
In a large cohort study (19), 1,517 patients with rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE), SSc, Sjögren’s 
syndrome (SS), mixed connective tissue disease (MCTD), and pol-
ymyositis/dermatomyositis (PM/DM) were evaluated for thyroid 
dysfunctions clinically and by imaging and fine-needle aspiration 
cytology [with respect to prevalence of GD or Hashimoto’s thy-
roiditis (HT) in the general population]. HT was more common 
among MCTD, SS, and RA patients (21, 7, and 6%, respectively) 
than GD (2.5, 3, and 1.6%, respectively). SLE, RA, SSc, MCTD, 
SS, and PM/DM had a higher prevalence for HT than the general 
population of 90-, 160-, 220-, 556-, 176-, and 69-fold, respectively, 
and for GD of 68-, 50-, 102-, 76-, 74-, and 37-fold, respectively.
A first study (20) aimed to assess the prevalence of thyroid 
disorders in SSc patients using a complete thyroid work-up, 
versus an internal appropriate control group. Two hundred 
two SSc patients versus 404 controls from the general popula-
tion (matched by age and gender, with similar iodine intake) 
were evaluated for TSH, FT3, FT4, AbTg and AbTPO, thyroid 
ultrasonography and blood flow, and fine needle aspiration when 
needed. Odds ratios (OR) for female SSc versus controls subjects 
were significant for: clinical hypothyroidism, 14.5 (2.3–90.9); 
subclinical hypothyroidism, 3.2 (1.8–5.7); AbTPO positivity, 
2.7 (1.8–4.1); thyroid hypoechoic pattern, 3.2 (2.2–4.7); thyroid 
autoimmunity, 3.7 (2.6–5.4); and thyroid volume <6 mL, 1.8 
(1.2–2.7). OR for thyroid autoimmunity in male SSc patients ver-
sus control subjects was 10.8 (2.2–52.4). Female SSc patients had 
mean TSH levels significantly higher than control subjects, and 
female and male SSc patients had significantly higher AbTPO 
than controls. Three cases of GD in female SSc (versus zero in 
controls, P < 0.05), and two of papillary thyroid cancer (PTC) 
were reported in SSc patients.
The authors suggested to test thyroid function, AbTPO, and 
ultrasonography and to assess the clinical profile of SSc patients. 
Thyroid function follow-up (and appropriate treatments) should 
be performed periodically in women, subjects with positive 
AbTPO and hypoechoic and small thyroid.
The abovementioned results were confirmed in another study 
(21) that evaluated thyroid function and autoantibodies, in 79 
SSc women, versus 81 age-matched women with osteoarthritis 
(OA) as controls. Hypothyroidism was found in 16 of 79 (20%) 
patients with SSc and in 9 of 81 (11%) patients with OA. AbTPO 
were present in 23% SSc versus 11% controls. The risk of hypo-
thyroidism was significantly higher in AbTPO-positive patients 
(P < 0.0001).
A cross-sectional study (22) of two convenience samples of 
patients with SSc, one in Canada and the other in Colombia, 
was performed. Among 719 patients, 273 (38%) had at least one 
other autoimmune disease. Three hundred sixty-six autoimmune 
diseases were assessed, among which AITD (38%), RA (21%), SS 
(18%), and primary biliary cirrhosis (4%) were more frequent. 
Two hundred sixty patients (36%) had first-degree relatives with 
at least one autoimmune disease [RA (18%) and AITD (9%) were 
the most common]. These results suggest that polyautoimmun-
ity is frequent in SSc patients and autoimmune diseases cluster 
within families of these patients.
To determine (23) the ATA prevalence in a large SSc cohort 
and to verify whether they are associated with distinct clinical 
phenotypes, 138 SSc patients (46 with dSSc and 92 with lSSc) 
and 100 healthy controls (HC) were tested for AbTg and AbTPO. 
A statistically significant increase of AbTPO was detected only in 
patients with lSSc compared to HC (32.6 versus 14%, P = 0.003).
Two hundred ten SSc patients were evaluated in a Japanese 
study (24), that identified 30 patients with AITD (14.3%), includ-
ing 29 with HT (13.8%) and 1 with GD (0.5%).
A further study (25) first evaluated the incidence of new cases 
of clinical and subclinical thyroid dysfunction in SSc women ver-
sus controls from the same geographic area (matched by gender 
and age). SSc patients with thyroid dysfunction were excluded 
at the beginning, and then the manifestation of new cases of 
thyroid disorders was assessed in 179 patients and 179 matched 
controls, having a similar iodine intake (median follow-up: 
94 months in controls; 73 months in SSc). An elevated incidence 
(P < 0.05) of new cases of hypothyroidism, thyroid dysfunction, 
AbTPO positivity, and hypoechoic thyroid, in SSc patients (15.5, 
21, 11, and 14.6 of 1,000 patients per year; respectively) versus 
those in controls was observed. The onset of hypothyroidism was 
demonstrated (by logistic regression analysis) to be related to a 
borderline elevated initial TSH value, the presence of high AbTPO 
levels, and a hypoechoic and small thyroid in SSc patients.
A subsequent study (26) confirmed a high prevalence of 
subclinical hypothyroidism (8.5%), overt hypothyroidism (1.9%), 
subclinical hyperthyroidism (2.8%), and overt hyperthyroidism 
(0.9%) in SSc patients, and that a small thyroid volume (<4.5 ml) 
was related to hypothyroidism.
Positive ATA titers were also observed in 27/86 SSc Polish (27) 
patients (31%).
Recently, it has been also demonstrated that hypovitaminosis 
D was statistically associated with AT in SSc patients (28).
Conversely, a recent study (29) evaluated prospectively the 
prevalence of other autoimmune disorders in outpatient clinic in 
3,069 consecutive patients with diagnosed chronic AT, with respect 
to two control groups (matched by age and gender): (a) a control 
group of 1,023 subjects, drawn out a random sample of the general 
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population without thyroid disorders and (b) 1,023 patients with 
non-toxic multinodular goiter extracted from the same random 
sample of the general population, with similar iodine intake. The 
results of the study demonstrated a significant increase of the 
prevalence of SSc in AT patients (with respect to both controls).
Different studies demonstrate elevated circulating CXCL10 
(Th1) and CCL2 (Th2) chemokines in SSc patients of newly diag-
nosis. Patients with a serious clinical phenotype, including the 
involvement of lung and kidney, have higher CXCL10. CXCL10 
declines during the follow-up, while CCL2 does not change, sug-
gesting the progress from a beginning Th1 inflammatory stage to 
a successive Th2 phase (30, 31).
Th1 lymphocytes, interferon-γ, and interferon-γ-dependent 
chemokines (CXCL9, CXCL10, CXCL11) play a pivotal role in 
AITD, that are Th1 immune-mediated autoimmune disorders, 
too (32–35). Newly diagnosed SSc patients have elevated circulat-
ing levels of CXCL10, but not of CCL2, in the presence of AT, 
indicating a predominance of the Th1 immune response in these 
patients (36).
To sum up, the abovementioned data show a high incidence, 
and prevalence, of new cases of AT, and hypothyroidism, in 
patients with SSc, suggesting that in SSc women, with a borderline 
high (though in the normal range) TSH level, in the presence of 
AbTPO, and a hypoechoic and small thyroid, it could be neces-
sary to monitor periodically thyroid function.
SSc AND GD
A first anectodal study reported an association of SSc and GD in 
three cases (37). One case of GD was also observed among 210 
SSc Japanese patients (0.5%) (24). Graves’ ophthalmopathy has 
been also occasionally reported in one SSc patient (38).
A significant number (3 cases) of GD in female SSc (3/202 ver-
sus 0/404 controls, P < 0.05) was also observed in a case control 
study (20), with an internal appropriate control group.
On the whole the abovementioned studies suggest a higher 
prevalence of GD in SSc patients; nevertheless further studies, 
involving a larger number of SSc patients, are necessary to con-
firm this finding.
SSc AND PTC
Single cases of PTC in association with SSc were reported in 
several studies (9, 20, 39–42).
However, more recently, the risk of TC in 327 unselected SSc 
patients with respect to two population-based, control groups 
was studied systematically (matched by age and gender; 654 
subjects from an iodine-deficient area and 654 subjects from an 
iodine-sufficient area) (43).
Six subjects with PTC were detected among SSc patients, 
while only one case was observed in controls 1, as well in con-
trols 2 (P = 0.007, for both). In SSc, all patients with TC showed 
thyroid autoimmunity versus 40% of the other SSc patients 
(P = 0.001) (43).
These findings suggest the possibility of a increased prevalence 
of PTC in SSc patients with thyroid autoimmunity, however, 
larger cohorts are needed to elucidate this.
CLINICAL ASPECTS OF SSc AND 
THYROID DISORDERS
Several studies have evaluated a possible association among thyroid 
disorders and clinical findings of SSc, reporting different results.
It was initially reported that patients with hypothyroidism had 
more frequently subcutaneous calcinosis (11).
Hungarian SSc patients with AbTPO concentration tended to 
have secondary SS (15).
In a further study in female patients with SSc (dura-
tion < 3 years), FT4 levels correlated significantly with Dlco% 
(r = + 0.90, P < 0.01), while in patients with SSc duration > 3 years 
hypothyroidism correlated significantly with hand joint restric-
tion of motion (17).
Seventeen SSc patients with high pulmonary systolic pres-
sure (>35 mmHg) were studied in another article (44). High 
pulmonary pressure in these SSc patients was not associated 
with the type of SSc, or age; however, five SSc patients (12.5%) 
had alteration of the thyroid function (two cases of hypothy-
roidism, three of hyperthyroidism). The pulmonary pressure 
levels were higher in SSc patients with thyroid dysfunction, 
with respect to SSc in euthyroidism (40 versus 31  mmHg, 
respectively; P < 0.05). Furthermore, hypothyroid SSc patients 
had higher pressure levels, with respect to hyperthyroid SSc 
(46 versus 37 mmHg, respectively), even if not significantly. 
The lack of significant differences in pressure levels between 
hypothyroid, or hyperthyroid SSc, and the low frequency of 
ATA in pulmonary hypertension associated with SSc, suggest 
a vasomotor role of thyroid hormones, rather than an autoim-
mune mechanism (44).
In Japanese female SSc patients, the prevalence of anticen-
tromere antibody positivity, SS, and severe facial skin sclerosis 
was significantly prevalent in the presence of AITD (24).
A study found a statistically significant increase of AbTPO 
only in patients with lSSc (but not in dSSc) compared to controls 
(32.6 versus 14%, P = 0.003) (23).
To sum up, most of the abovementioned studies did not 
observed any association among thyroid dysfunctions and/
or autoimmunity and features of SSc (clinical or serological) 
(13, 20, 25, 27).
CONCLUSION
Many studies have shown a high incidence, and/or prevalence, of 
new cases of AT, and hypothyroidism in SSc patients, especially 
in the female gender. An association among a Th1 predominance, 
low levels of vitamin D, and AITDs has been also demonstrated 
in patients with SSc.
Few cases of GD have been also described in SSc patients, 
according with the higher prevalence of thyroid autoimmunity.
It has been also observed a higher prevalence of PTC, in asso-
ciation with AT, in SSc patients. However, in order to confirm 
results about GD and TC, studies in larger number of patients 
with SSc are needed.
To sum up, the abovementioned data strongly suggest that 
female SSc patients with a high risk (a borderline high though 
normal TSH value, the presence of AbTPO, and a hypoechoic 
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and small thyroid) should be periodically monitored for thyroid 
function, and appropriate treatments when needed.
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